All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Is PIVKA-II a Promising Biomarker for Hepatocellular Carcinoma?

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F20%3A10410976" target="_blank" >RIV/00216208:11140/20:10410976 - isvavai.cz</a>

  • Alternative codes found

    RIV/00669806:_____/20:10410976

  • Result on the web

    <a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=gFjC6EEako" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=gFjC6EEako</a>

  • DOI - Digital Object Identifier

Alternative languages

  • Result language

    angličtina

  • Original language name

    Is PIVKA-II a Promising Biomarker for Hepatocellular Carcinoma?

  • Original language description

    Aim. To evaluate the clinical contribution of protein induced by vitamin K absence (PIVKA-II) for the diagnosis of hepatocellular carcinoma (HCC). The second aim was to compare PIVKA-II with routinely used alpha-fetoprotein (AFP) for the same indication. Materials and methods. 310 participants were enrolled in our study: 60 with HCC, 40 with liver metastases of colorectal cancer origin, 40 with liver cirrhosis, 20 with pancreatic cancer (PC) and 150 healthy individuals. Serum levels of PIVKA-II were measured using a chemiluminescent assay of the Architect 1000i System (&quot;Abbott&quot;, USA) and AFP levels using a chemiluminescent assay by DxI 800 (&quot;Beckman Coulter&quot;, USA). Serum concentrations of PIVKA-II and AFP were compared between the group with HCC and the other mentioned groups. Results. PIVKA-II achieved better clinical sensitivity in comparison with AFP. PIVKA-II achieved its best sensitivity (96,9 %) in distinguishing between the HCC and control group with the proposed cut-off value of 60 mAU/ml. Conclusion. PIVKA-II can be used alongside routinely established AFP as a valuable marker in the diagnosis of HCC.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>ost</sub> - Miscellaneous article in a specialist periodical

  • CEP classification

  • OECD FORD branch

    30204 - Oncology

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2020

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Astrachanskij medicinskij žurnal

  • ISSN

    1992-6499

  • e-ISSN

  • Volume of the periodical

    15

  • Issue of the periodical within the volume

    1

  • Country of publishing house

    RU - RUSSIAN FEDERATION

  • Number of pages

    4

  • Pages from-to

    6-9

  • UT code for WoS article

  • EID of the result in the Scopus database